ABEO vs. IMUX, RNAC, VTGN, COYA, KPTI, CLRB, NVCT, OPTN, SCTL, and RZLT
Should you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Immunic (IMUX), Cartesian Therapeutics (RNAC), Vistagen Therapeutics (VTGN), Coya Therapeutics (COYA), Karyopharm Therapeutics (KPTI), Cellectar Biosciences (CLRB), Nuvectis Pharma (NVCT), OptiNose (OPTN), Societal CDMO (SCTL), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.
Immunic (NASDAQ:IMUX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
51.8% of Immunic shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 3.0% of Immunic shares are held by company insiders. Comparatively, 5.3% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Immunic and Immunic both had 7 articles in the media. Immunic's average media sentiment score of 0.48 beat Abeona Therapeutics' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.
Immunic currently has a consensus target price of $8.50, indicating a potential upside of 569.29%. Abeona Therapeutics has a consensus target price of $36.00, indicating a potential upside of 718.18%. Given Immunic's higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Immunic.
Abeona Therapeutics' return on equity of -157.44% beat Immunic's return on equity.
Immunic has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.
Abeona Therapeutics has higher revenue and earnings than Immunic. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
Abeona Therapeutics received 419 more outperform votes than Immunic when rated by MarketBeat users. Likewise, 70.27% of users gave Abeona Therapeutics an outperform vote while only 65.73% of users gave Immunic an outperform vote.
Summary
Abeona Therapeutics beats Immunic on 9 of the 14 factors compared between the two stocks.
Get Abeona Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abeona Therapeutics Competitors List
Related Companies and Tools
